Laboratory diagnosis of the antiphospholipid syndrome: a plethora of obstacles to overcome

被引:66
作者
Devreese, Katrien [1 ]
Hoylaerts, Marc F. [2 ]
机构
[1] Ghent Univ Hosp, Lab Clin Biol, Coagulat Lab, Dept Clin Chem Microbiol & Immunol, B-9000 Ghent, Belgium
[2] Univ Leuven, Ctr Mol & Vasc Biol, Louvain, Belgium
关键词
antiphospholipid syndrome; antiphospholipid antibodies; lupus anticoagulants; anticardiolipin; beta(2)-glycoprotein I; thrombin generation; INTERNATIONAL CONSENSUS STATEMENT; ANTI-PROTHROMBIN ANTIBODIES; GLYCOPROTEIN-I ANTIBODIES; LUPUS-ANTICOAGULANTS; ANTICARDIOLIPIN ANTIBODIES; THROMBIN GENERATION; MONOCLONAL-ANTIBODIES; CLASSIFICATION CRITERIA; EUROPEAN-FORUM; RISK-FACTOR;
D O I
10.1111/j.1600-0609.2009.01243.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The antiphospholipid antibody syndrome (APS) is defined by two major elements: the presence in plasma of auto-antibodies, i.e. antiphospholipid antibodies and the occurrence of clinical features, categorised as vascular thrombosis or pregnancy morbidity. In contrast to recent reviews on the physiopathology of APS, the present review focuses on the laboratory diagnosis of APS. The original clinical and laboratory criteria that defined patients with APS were set in 1998 in the so-called Sapporo criteria. Although a revision of these criteria was published in 2006, a number of questions on the laboratory diagnosis of APS remain unresolved. The highlight in this review will therefore be on the potential and limitations of the detection of the lupus anticoagulant, as an established laboratory criterion for the diagnosis of APS. The strengths and weaknesses of the current laboratory guidelines are discussed against our current insight in the physiopathology of APS.
引用
收藏
页码:1 / 16
页数:16
相关论文
共 119 条
[1]  
Arnout J, 1998, THROMB HAEMOSTASIS, V79, P955
[2]  
Arnout J, 1999, THROMB HAEMOSTASIS, P70
[3]  
Arnout J, 1999, THROMB HAEMOSTASIS, V81, P929
[4]  
Arnout J, 2001, THROMB HAEMOSTASIS, V86, P83
[5]   OPTIMIZATION OF THE DILUTE PROTHROMBIN TIME FOR THE DETECTION OF THE LUPUS ANTICOAGULANT BY USE OF A RECOMBINANT TISSUE THROMBOPLASTIN [J].
ARNOUT, J ;
VANRUSSELT, M ;
HUYBRECHTS, E ;
VERMYLEN, J .
BRITISH JOURNAL OF HAEMATOLOGY, 1994, 87 (01) :94-99
[6]   Comparison of different kits in the detection of autoantibodies to cardiolipin and beta2glycoprotein 1 [J].
Audrain, MAP ;
Colonna, F ;
Morio, F ;
Hamidou, MA ;
Muller, JY .
RHEUMATOLOGY, 2004, 43 (02) :181-185
[7]   Value of autoantibodies to β2-glycoprotein 1 in the diagnosis of antiphospholipid syndrome [J].
Audrain, MAP ;
El Kouri, D ;
Hamidou, MA ;
Mioche, L ;
Ibara, A ;
Langlois, ML ;
Muller, JY .
RHEUMATOLOGY, 2002, 41 (05) :550-553
[8]  
Bertolaccini ML, 2001, J RHEUMATOL, V28, P2637
[9]   Anti-prothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: a 15-year longitudinal study [J].
Bizzaro, N. ;
Ghirardello, A. ;
Zampieri, S. ;
Jaccarino, L. ;
Tozzoli, R. ;
Ruffatti, A. ;
Villalta, D. ;
Tonutti, E. ;
Doria, A. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (06) :1158-1164
[10]  
Blanco AN, 2002, HAEMATOLOGICA, V87, P271